SuperworthCorcept Therapeutics shares outstanding CORT
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 118.4M
- On a year earlier
- −1.7%
- fewer shares
Corcept Therapeutics had 118.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 1.7% fewer than a year earlier, so each share owns a little more of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 120M | +1% |
| FY2024 | 119.2M | +8% |
| FY2023 | 110.8M | −5% |
| FY2022 | 116.4M | −5% |
| FY2021 | 122.4M | −3% |
| FY2020 | 126.7M | +3% |
| FY2019 | 122.8M | −2% |
| FY2018 | 125.3M | −2% |
| FY2017 | 127.8M | +7% |
| FY2016 | 119M | +9% |
| FY2015 | 109.2M | +8% |
| FY2014 | 101.3M | +1% |
| FY2013 | 99.8M | +0% |
| FY2012 | 99.8M | +18% |
| FY2011 | 84.2M | +16% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 118.4M | −2% | |
| Q1 FY26 | 104.4M | −13% | |
| Q4 FY25 | 120M | +1% | |
| Q3 FY25 | 119.4M | +5% | |
| Q2 FY25 | 120.5M | +8% | |
| Q1 FY25 | 119.8M | +9% | |
| Q4 FY24 | 119.2M | +8% | |
| Q3 FY24 | 113.7M | +2% | |
| Q2 FY24 | 111.2M | +2% | |
| Q1 FY24 | 109.9M | −5% | |
| Q4 FY23 | 110.8M | −5% | |
| Q3 FY23 | 111.1M | −5% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Corcept Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.